BiotechTube
Origenis

Origenis

Martinsried, Germany· Est.
origenis.de
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Origenis is a private, preclinical-stage biotech firm utilizing an integrated AI and wet-lab platform to pioneer small molecule therapeutics for underserved diseases. Its core technology, featuring components like Cippix®, MolMind®, and MOREsytem®, enables the design and optimization of novel compounds with a focus on tissue-specific delivery, particularly to the brain and eye. The company has established early validation through historical and potentially ongoing collaborations with entities like Vivoryon and Alcon, and is advancing internal pipelines in neurodegeneration, brain cancer, and ophthalmology.

NeurodegenerationOncologyOphthalmology

Technology Platform

Integrated AI-driven platform comprising Cippix® (IP analytics), MolMind® (AI drug design & synthesis planning), MOREsytem® (wet-lab integration & feedback loop), and specialized tissue-targeting assays (BRAINstorm™, EYEdeal™).

Opportunities

Origenis targets high-value, underserved markets in CNS and ophthalmology where biological barriers have stymied traditional drug discovery.
Its integrated AI platform offers a potential paradigm shift in efficiency and success rates for early-stage small molecule design, creating significant partnership and asset value opportunities.

Risk Factors

Key risks include the unproven clinical translation of its AI-designed molecules, ongoing pre-revenue funding requirements in a competitive capital environment, and the need to secure major pharmaceutical partnerships to advance programs through costly clinical development.

Competitive Landscape

Origenis competes in the rapidly growing AI-drug discovery sector against companies like Exscientia, Recursion, and BenevolentAI, as well as traditional biopharma. Its differentiation lies in the tight integration of AI with proprietary wet-lab data and a specific focus on overcoming the blood-brain and eye film barriers.

More companies in Small Molecule Drugs →More companies in Germany →